Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus Bevacizumab.

doi:10.21873/anticanres.12097

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus Bevacizumab.

Anticancer research - 1 Nov 2017

Wills Beatriz, Cardona Andrés F, Rojas Leonardo, Ruiz-Patiño Alejandro, Arrieta Oscar, Reguart Noemí, Carranza Hernán, Vargas Carlos, Otero Jorge, Corrales Luis, Martín Claudio, Cuello Mauricio, Pino Luis Eduardo, Rolfo Christian, Rosell Rafael, Zatarain-Barrón Zyanya Lucia

Abstract excerpt

BACKGROUND: Heavily treated patients with non-small cell lung cancer (NSCLC) have few treatment options, while irinotecan and bevacizumab have proven synergistic action in preclinical studies. PATIENTS AND METHODS: A total of 49 patients with heavily treated NSCLC were enrolled from 2011-2014 and treated with irinotecan and bevacizumab. Treatment response along with mutational status of epidermal growth factor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bevacizumab

Share to Camptothecin

Share to Disease-Free Survival

Share to Drug Administration Schedule

Share to Irinotecan

Share to Survival Analysis

Share to Tissue Inhibitor of Metalloproteinase-1

Source

Open in PubMed

Identifiers

PMID: 29061829
DOI: 10.21873/anticanres.12097

Genes

EGFR
TIMP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus Bevacizumab.PMID 29061829Read ↗

The efficacy and safety of immune checkpoint inhibitors for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy: A systematic review and network meta-analysis.Semantic proximity Read ↗

Neoadjuvant immunochemotherapy vs. neoadjuvant targeted therapy plus chemotherapy for EGFR-mutated non-small cell lung cancer: a retrospective study.Semantic proximity Read ↗

A retrospective study on the efficacy and safety of Endostar with chemotherapy in EGFR-TKI-resistant NSCLC.Semantic proximity Read ↗

Immunotherapy-based therapy as a promising treatment for EGFR-mutant advanced non-small cell lung cancer patients after EGFR-TKI resistance.Semantic proximity Read ↗

A retrospective real-world study: the efficacy of immune-related combination therapies in advanced non-small cell lung cancer after resistance to EGFR-TKIs.Semantic proximity Read ↗

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.Semantic proximity Read ↗

Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301.Semantic proximity Read ↗

Clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR-mutated advanced non-small-cell lung.Semantic proximity Read ↗

Multi-target angiogenesis inhibitor combined with PD-1 inhibitors may benefit advanced non-small cell lung cancer patients in late line after failure of EGFR-TKI therapy.Semantic proximity Read ↗

Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer.Semantic proximity Read ↗

Microwave ablation with continued EGFR tyrosine kinase inhibitor therapy prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

EGFR‐TKIs plus local therapy demonstrated survival benefit than EGFR‐TKIs alone in EGFR‐mutant NSCLC patients with oligometastatic or oligoprogressive liver metastasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.